ADAM19在子宫内膜癌组织中的表达及临床意义

目的:研究adamalysin19 (ADAM19)在子宫内膜癌中的表达以及相关的临床特征、病理特点. 方法:应用免疫组织化学的方法检测51例子宫内膜癌、33例正常子宫内膜中ADAM19蛋白的表达情况,并分析与临床特征及病理学特点的关系.结果:ADAM19蛋白在子宫内膜癌中的表达明显高于正常子宫内膜组织,两者比较差异有统计学意义(P＜0.001);病理类型为腺鳞癌、鳞状细胞癌、浆液性乳头状腺癌、透明细胞癌、未分化癌等类型者ADAM19的表达明显高于子宫内膜样癌及腺棘癌(P＝0.042);组织学低分化、无分化者的表达明显高于中高分化者(P＝0.028);有肌层浸润者ADAM19的表达有高于无肌层侵润者的趋势(P＝0.065);但临床资料显示ADAM19的表达与临床分期、淋巴结转移无明显相关性(P＝0.328及P＝0.529).结论:子宫内膜癌组织中ADAM19蛋白呈过表达,ADAM19与子宫内膜癌的病程进展及预后相关,有可能成为一新的临床观察指标.

Expression and clinical significance of ADAM 19 in endometrial carcinoma

OBJECTIVE: To investigate the expression of adamalysin19 (ADAM19) in human endometrial carcinoma and to explore its correlation with clinical behavior and pathological characters. METHODS: Immunohistochemistry was conducted to detect the expression of ADAM19 in the endometrial tissue from 51 patients with endometrial carcinoma and 33 patients with normal endometrium.The results were analyzed with clinical data.RESULTS: Postive expression signals of ADAM19 were detected both in the endome-trial cancer tissue and normal endometrium. The expression level of ADAM19 in endometrial cancer tissue was significantly higher than that in normal endometrium (P<0.001).Those with lower histological grade or non-adenocarcinoma had a higher expression level(P=0.028 , P=0.042). In addition, ADAM19 in thecarcinoma with myometrial invasion had a higher expression trend than that without myometrial invasion (P=0.065). However, from the clinical data we found no correlation with surgical staging and metastasis of lymph nodes(P=0.328, P=0.529). CONCLUSION: The overexpression of ADAM19 suggests that ADAM19 correlates with the progress and prognosis of endometrial carcinoma, and may be implicated as a marker for the clinical behavior of endometrial carcinoma.